Impact of 13-valent pneumococcal conjugate vaccine on laboratory-confirmed pneumococcal meningitis and purulent meningitis among children ˂5 years in Cameroon, 2011-2018

• Published in: PloS one Vol. 16; no. 4; p. e0250010
• Main Authors: Njuma Libwea, John, A Fletcher, Mark, Koki Ndombo, Paul, Boula, Angeline, Ashukem, Nadesh Taku, Ngo Baleba, Madeleine, Kingue Bebey, Rachel Sandrine, Nkolo Mviena, Eric Gaston, Tageube, Jean, Kobela Mbollo, Marie, Koulla-Shiro, Sinata, Madhi, Shabir, Njanpop-Lafourcade, Berthe-Marie, Mohammad, Ali, Begier, Elizabeth, Southern, Joanna, Beavon, Rohini, Gessner, Bradford
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 15.04.2021; Public Library of Science (PLoS)
• Subjects: Age; Bacterial meningitis; Biology and Life Sciences; Cerebrospinal fluid; Children; Children & youth; Clinical trials; Conjugates; Data collection; Decision analysis; Demographic aspects; Developing countries; Drug dosages; Editing; Emerging markets; Funding; Health surveillance; Hospitals; Immunization; Infectious diseases; Laboratories; LDCs; Medical research; Medicine; Medicine and Health Sciences; Meningitis; Methodology; People and Places; Physiological aspects; Pneumonia; Prevention; Public health; Research and Analysis Methods; Reviews; Schedules; Serotypes; Social sciences; Streptococcus infections; Surveillance; Testing; Vaccines; Visualization; Finland; New York; Cameroon; United States > US; Africa; South Africa; France; Sub-Saharan Africa

The 13-valent pneumococcal conjugate vaccine (PCV13) entered Cameroon's childhood national immunization programme (NIP) in July 2011 under a 3-dose schedule (6, 10, 14 weeks of age) without any catch-up. We described the impact of PCV13 onserotype distribution among pneumococcal meningitis case...